We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Advanced Prostate Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
David Mutchnik
Apr 21, 2015
get psa and follow
radiation if psa rises
Charles Maack
Apr 21, 2015
The tertiary grade 5 is of concern, not so much the margins since lymph nodes showed negative and I expect seminal vesicles and vas deferens showed same. Because of the tertiary grade 5 PSA should certainly be followed and if level post surgical removal is 0.1ng/ml or over I would expect a period of ADT as well as salvage radiation considered since we would hope continued cancer cell activity remains prostatic bed confined...possibly in pelvic lymph nodes if samples not extracted for pathological review
michael hermans
Apr 21, 2015
is he potent preop? i would like him to maximize continence control. i would get a psa at 3 months and strongly consider xrt if psa gets to 0.4.i would encourage him to see a radiation oncologist to get their rationale for this situation.in my experinence it varies all over the place.
Tarek Osman
Apr 22, 2015
Yes I would advise him radiotherapy after I know the post prostatectomy nadir PSA.
If he refuses radiotherapy I wil follow his PSA every 3 months. Thanks
Marius Markevicius
Apr 22, 2015
I would sent patient to adjuvant radiotherapy. PSA schedule would be after 1, 3, 6, 9, 12 month notwithstanding radiotherapy. If patient do not agree, I would follow him using the same PSA schedule.
Tony Nimeh
Apr 23, 2015
Thank you for your recommendations. Yes, he is potent preop. We will closely follow his PSA and refer him to a radiation oncologist to get the conversation started in case it becomes necessary.
Dec 26, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
David Mutchnik
Apr 21, 2015
Charles Maack
Apr 21, 2015
michael hermans
Apr 21, 2015
Tarek Osman
Apr 22, 2015
Marius Markevicius
Apr 22, 2015
Tony Nimeh
Apr 23, 2015
Dec 26, 2024
Pending Moderator approval.